Overview

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Status:
Not yet recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals